Clinical trial · Observational
Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients
Treatment Strategies for Myeloproliferative Neoplasms by Targeting the Tumor Suppressor P53
NCT01970930CI-TRIAL-00031271completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to isolate and characterize stem cells of patients with Polycythemia Vera (PV) and Essential Thrombocythemia (ET) to find out why these cells are not working the way they should be and why they seem to be sensitive to regulatory factors in the blood, such as clotting.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Essential Thrombocythemia | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.98 |
| Polycythemia Vera | Polycythemia Vera | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood specimen | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- PV or ET
- description
- subject who has polycythemia vera or essential thrombocythemia
- interventionNames
- Procedure: Blood specimen
Primary outcomes (1)
- measure
- Stem cell function
- timeFrame
- at one time study visit
- description
- Assess the effects of RG7112 on MPN HSC/HPC p53 levels and study how it affects MPN stem cell function.
Secondary outcomes (1)
- measure
- CD34+ cells assays
- timeFrame
- at one time study visit
- description
- Assess the effects of a combination of low doses of IFNα and RG7112 on MPN HSC/HPC. After treatment with RG7112 and IFNα at the various doses, p53, MDM2, MDMX, phosphor-p38, and phosphor-STAT1 levels in MPN CD34+ cells will be measured using monoclonal antibody staining and flow cytometric and immunofluorescence analyses.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * polycythemia vera or essential thrombocythemia * agree to give blood for study Exclusion Criteria: * none
References
Publications (0)
Data not yet available
No reference posted for this study.